Brind.

Ascendis Pharma's TransCon CNP is under U.S. FDA priority review, and the company aims to fulfill Vision 2030.

Steady: 0 in the last 7 days Updated sep 17

The latest in this situation

  1. Collaboration between Novo Nordisk and Ascendis Pharma terminated regarding TransCon products.

How it started

3 reports, 2 independent, last reported Aug 1. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Ascendis Pharma's TransCon CNP is under U.S. FDA priority review, and the company aims to fulfill Vision 2030.

Who's involved

What this event is mainly about
FDAVision 2030

How it developed

Newest first. Tap a step to see who reported it.
  1. Collaboration between Novo Nordisk and Ascendis Pharma terminated regarding TransCon products.Sub-event
  2. Ascendis Pharma's TransCon CNP is under FDA priority review.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireAscendis Pharma Reports Second Quarter 2025 Financial Results – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Rev
  • Unknown outlet